Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization

EBioMedicine

Volumn 9, Issue , 2016, Pages 61-76

  Feng, Xiujing ^a   Weng, Dan ^b   Zhou, Feifei ^a   Owen, Young D ^c   Qin, Haohan ^a   Zhao, Jingfa ^a   WenYu, ^a   Huang, Yahong ^a   Chen, Jiajia ^a   Fu, Haijian ^a   Yang, Nanfei ^a   Chen, Dianhua ^a   Li, Jianxin ^a   Tan, Renxiang ^a   Shen, Pingping ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Apigenin; Macrophage polarization; NF B; Obesity related inflammation; PPAR

Indexed keywords

ALANINE AMINOTRANSFERASE; APIGENIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BINDING;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL INFILTRATION; CELL VIABILITY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ISOTHERMAL TITRATION CALORIMETRY; LUCIFERASE ASSAY; MACROPHAGE; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; OBESITY; PHAGOCYTOSIS; POLARIZATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; STEATOSIS; WESTERN BLOTTING; ADIPOSE TISSUE; AGONISTS; ANIMAL; CELL LINE; CHEMISTRY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; MACROPHAGE ACTIVATION; METABOLIC SYNDROME X; METABOLISM; PATHOLOGY; PERITONEUM MACROPHAGE; PHENOTYPE; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; APIGENIN; BIOMARKERS; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOPHENOTYPING; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGES; MACROPHAGES, PERITONEAL; MALE; METABOLIC SYNDROME X; MICE; NF-KAPPA B; OBESITY; PHENOTYPE; PPAR GAMMA; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84991721067     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.06.017     Document Type: Article

References (65)

1. Arango, D., Morohashi, K., Yilmaz, A., Kuramochi, K., Parihar, A., Brahimaj, B., Grotewold, E., Doseff, A.I., Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E2153–E2162.
2. Audic, S., Claverie, J.M., The significance of digital gene expression profiles. Genome Res. 7 (1997), 986–995.
3. Bao, X., Cui, J., Wu, Y., Han, X., Gao, C., Hua, Z., Shen, P., The roles of endogenous reactive oxygen species and nitric oxide in triptolide-induced apoptotic cell death in macrophages. J. Mol. Med. (Berl) 85 (2007), 85–98.
4. Bouhlel, M.A., Derudas, B., Rigamonti, E., Dievart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., Staels, B., Chinetti-Gbaguidi, G., PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6 (2007), 137–143.
5. Buckingham, R.E., Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33 (2005), 167–170.
6. Byun, S., Park, J., Lee, E., Lim, S., Yu, J.G., Lee, S.J., Chen, H.Y., Dong, Z.G., Lee, K.W., Lee, H.J., Src kinase is a direct target of apigenin against UVB-induced skin inflammation. Carcinogenesis 34 (2013), 397–405.
7. Chinetti-Gbaguidi, G., Staels, B., Macrophage polarization in metabolic disorders: functions and regulation. Curr. Opin. Lipidol. 22 (2011), 365–372.
8. Choi, J.S., Islam, M.N., Ali, M.Y., Kim, E.J., Kim, Y.M., Jung, H.A., Effects of C-glycosylation on anti-diabetic, anti-Alzheimer's disease and anti-inflammatory potential of apigenin. Food Chem. Toxicol. 64 (2014), 27–33.
9. Chung, S.W., Kang, B.Y., Kim, S.H., Pak, Y.K., Cho, D., Trinchieri, G., Kim, T.S., Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J. Biol. Chem. 275 (2000), 32681–32687.
10. Cipolletta, D., Feuerer, M., Li, A., Kamei, N., Lee, J., Shoelson, S.E., Benoist, C., Mathis, D., PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486 (2012), 549–553.
11. Dasu, M.R., Park, S., Devaraj, S., Jialal, I., Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 150 (2009), 3457–3464.
12. De Whalley, C.V., Rankin, S.M., Hoult, J.R., Jessup, W., Leake, D.S., Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem. Pharmacol. 39 (1990), 1743–1750.
13. Despres, J.P., Lemieux, I., Abdominal obesity and metabolic syndrome. Nature 444 (2006), 881–887.
14. Dinarello, C.A., Anti-inflammatory agents: present and future. Cell 140 (2010), 935–950.
15. Doshi, L.S., Brahma, M.K., Bahirat, U.A., Dixit, A.V., Nemmani, K.V., Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin. Investig. Drugs 19 (2010), 489–512.
16. Dou, W., Zhang, J.J., Zhang, E.Y., Sun, A.N., Ding, L.L., Chou, G.X., Wang, Z.T., Mani, S., Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-kappa B signaling pathway. J. Pharmacol. Exp. Ther. 345 (2013), 473–482.
17. Duncan, B.B., Schmidt, M.I., Pankow, J.S., Ballantyne, C.M., Couper, D., Vigo, A., Hoogeveen, R., Folsom, A.R., Heiss, G., Low-grade systemic inflammation and the development of type 2 diabetes — the atherosclerosis risk in communities study. Diabetes 52 (2003), 1799–1805.
18. Escande, C., Nin, V., Price, N.L., Capellini, V., Gomes, A.P., Barbosa, M.T., O'neil, L., White, T.A., Sinclair, D.A., Chini, E.N., Flavonoid apigenin is an inhibitor of the NAD + ase CD38: implications for cellular NAD + metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62 (2013), 1084–1093.
19. Feng, X., Qin, H., Shi, Q., Zhang, Y., Zhou, F., Wu, H., Ding, S., Niu, Z., Lu, Y., Shen, P., Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARgamma. Biochem. Pharmacol. 89 (2014), 503–514.
20. Fujisaka, S., Usui, I., Bukhari, A., Ikutani, M., Oya, T., Kanatani, Y., Tsuneyama, K., Nagai, Y., Takatsu, K., Urakaze, M., Kobayashi, M., Tobe, K., Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58 (2009), 2574–2582.
21. Gregoire, F.M., Zhang, F., Clarke, H.J., Gustafson, T.A., Sears, D.D., Favelyukis, S., Lenhard, J., Rentzeperis, D., Clemens, L.E., Mu, Y., Lavan, B.E., MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol. Endocrinol. 23 (2009), 975–988.
22. Guevara, I., Iwanejko, J., Dembinska-Kiec, A., Pankiewicz, J., Wanat, A., Polus, A., Golabek, I., Bartus, S., Malczewska-Malec, M., Szczudlik, A., Determination of nitrite/nitrate in human biological material by the simple Griess reaction. Clin. Chim. Acta 274 (1998), 177–188.
23. Ha, S.K., Lee, P., Park, J.A., Oh, H.R., Lee, S.Y., Park, J.H., Lee, E.H., Ryu, J.H., Lee, K.R., Kim, S.Y., Apigenin inhibits the production of NO and PGE(2) in microglia and inhibits neuronal cell death in a middle cerebral artery occlusion-induced focal ischemia mice model. Neurochem. Int. 52 (2008), 878–886.
24. Havsteen, B.H., The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96 (2002), 67–202.
25. Higgins, L.S., Depaoli, A.M., Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am. J. Clin. Nutr. 91 (2010), 267S–272S.
26. Higgins, L.S., Mantzoros, C.S., The Development of INT131 as a Selective PPAR. Modulator: Approach to a Safer Insulin Sensitizer. PPAR Research, 2008.
27. Hou, Y., Moreau, F., Chadee, K., PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65. Nat. Commun., 3, 2012, 1300.
28. Howe, L.R., Subbaramaiah, K., Hudis, C.A., Dannenberg, A.J., Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin. Cancer Res. 19 (2013), 6074–6083.
29. Hu, J., Nakano, H., Sakurai, H., Colburn, N.H., Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Carcinogenesis 25 (2004), 1991–2003.
30. Kawai, Y., Nishikawa, T., Shiba, Y., Saito, S., Murota, K., Shibata, N., Kobayashi, M., Kanayama, M., Uchida, K., Terao, J., Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J. Biol. Chem. 283 (2008), 9424–9434.
31. Kiechl, S., Wittmann, J., Giaccari, A., Knoflach, M., Willeit, P., Bozec, A., Moschen, A.R., Muscogiuri, G., Sorice, G.P., Kireva, T., Summerer, M., Wirtz, S., Luther, J., Mielenz, D., Billmeier, U., Egger, G., Mayr, A., Oberhollenzer, F., Kronenberg, F., Orthofer, M., Penninger, J.M., Meigs, J.B., Bonora, E., Tilg, H., Willeit, J., Schett, G., Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19 (2013), 358–363.
32. Lee, J.Y., Jeong, H.J., Kim, M.K., Wee, W.R., Bone marrow-derived mesenchymal stem cells affect immunologic profiling of interleukin-17-secreting cells in a chemical burn mouse model. Korean J. Ophthalmol. 28 (2014), 246–256.
33. Lehrke, M., Lazar, M.A., The many faces of PPARgamma. Cell 123 (2005), 993–999.
34. Li, A.C., Brown, K.K., Silvestre, M.J., Willson, T.M., Palinski, W., Glass, C.K., Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106 (2000), 523–531.
35. Liang, Y.C., Huang, Y.T., Tsai, S.H., LIN-Shiau, S.Y., Chen, C.F., Lin, J.K., Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20 (1999), 1945–1952.
36. Liang, Y.C., Tsai, S.H., Tsai, D.C., Lin-Shiau, S.Y., Lin, J.K., Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett. 496 (2001), 12–18.
37. Liu, L.Z., Fang, J., Zhou, Q., Hu, X., Shi, X., Jiang, B.H., Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol. Pharmacol. 68 (2005), 635–643.
38. Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(T) (− Delta Delta C) method. Methods 25 (2001), 402–408.
39. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004), 677–686.
40. Marciano, D.P., Chang, M.R., Corzo, C.A., Goswami, D., Lam, V.Q., Pascal, B.D., Griffin, P.R., The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARgamma, RORs, and Rev-erbs. Cell Metab. 19 (2014), 193–208.
41. Mortazavi, A., Williams, B.A., Mccue, K., Schaeffer, L., Wold, B., Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5 (2008), 621–628.
42. Mueller, M., Lukas, B., Novak, J., Simoncini, T., Genazzani, A.R., Jungbauer, A., Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J. Agric. Food Chem. 56 (2008), 11621–11630.
43. Nicholas, C., Batra, S., Vargo, M.A., Voss, O.H., Gavrilin, M.A., Wewers, M.D., Guttridge, D.C., Grotewold, E., Doseff, A.I., Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J. Immunol. 179 (2007), 7121–7127.
44. Odegaard, J.I., Ricardo-Gonzalez, R.R., Goforth, M.H., Morel, C.R., Subramanian, V., Mukundan, L., Red Eagle, A., Vats, D., Brombacher, F., Ferrante, A.W., Chawla, A., Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447 (2007), 1116–1120.
45. Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., Yazaki, Y., Kadowaki, T., Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Investig. 101 (1998), 1354–1361.
46. Olefsky, J.M., Glass, C.K., Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72 (2010), 219–246.
47. Ouchi, N., Parker, J.L., Lugus, J.J., Walsh, K., Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11 (2011), 85–97.
48. Pascual, G., Fong, A.L., Ogawa, S., Gamliel, A., Li, A.C., Perissi, V., Rose, D.W., Willson, T.M., Rosenfeld, M.G., Glass, C.K., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005), 759–763.
49. Patsouris, D., Li, P.P., Thapar, D., Chapman, J., Olefsky, J.M., Neels, J.G., Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8 (2008), 301–309.
50. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., Glass, C.K., The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998), 79–82.
51. Salam, N.K., Huang, T.H., Kota, B.P., Kim, M.S., Li, Y., Hibbs, D.E., Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem. Biol. Drug Des. 71 (2008), 57–70.
52. Salam, N.K., Huang, T.H.W., Kota, B.P., Kim, M.S., Li, Y.H., Hibbs, D.E., Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem. Biol. Drug Des. 71 (2008), 57–70.
53. Saltiel, A.R., Olefsky, J.M., Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45 (1996), 1661–1669.
54. Sato, N., Kozar, R.A., Zou, L., Weatherall, J.M., Attuwaybi, B., Moore-Olufemi, S.D., Weisbrodt, N.W., Moore, F.A., Peroxisome proliferator-activated receptor gamma mediates protection against cyclooxygenase-2-induced gut dysfunction in a rodent model of mesenteric ischemia/reperfusion. Shock 24 (2005), 462–469.
55. Schmitz, M.L., Baeuerle, P.A., The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J. 10 (1991), 3805–3817.
56. Schwartz, A.V., Diabetes, TZDs, and Bone: a Review of the Clinical Evidence. PPAR Research, 2006.
57. Sheth, S.G., Gordon, F.D., Chopra, S., Nonalcoholic steatohepatitis (vol 126, pg 137, 1997). Ann. Intern. Med., 127, 1997, 658.
58. Straus, D.S., Glass, C.K., Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28 (2007), 551–558.
59. Weeks, B.A., Keisler, A.S., Myrvik, Q.N., Warinner, J.E., Differential uptake of neutral red by macrophages from three species of estuarine fish. Dev. Comp. Immunol. 11 (1987), 117–124.
60. Welton, A.F., Tobias, L.D., Fiedler-Nagy, C., Anderson, W., Hope, W., Meyers, K., Coffey, J.W., Effect of flavonoids on arachidonic acid metabolism. Prog. Clin. Biol. Res. 213 (1986), 231–242.
61. Willson, T.M., Lambert, M.H., Kliewer, S.A., Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001), 341–367.
62. Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., Chen, H., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112 (2003), 1821–1830.
63. Xu, H.Y., Barnes, G.T., Yang, Q., Tan, Q., Yang, D.S., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., Chen, H., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 112 (2003), 1821–1830.
64. Yang, W.S., Jeng, C.Y., Wu, T.J., Tanaka, S., Funahashi, T., Matsuzawa, Y., Wang, J.P., Chen, C.L., Tai, T.Y., Chuang, L.M., Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25 (2002), 376–380.
65. Yang, W.W., Lu, Y., Xu, Y.C., Xu, L.Z., Zheng, W., Wu, Y.Y., Li, L., Shen, P.P., Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J. Biol. Chem. 287 (2012), 40140–40149.